Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

In this Healio Video Perspective from Telling It Like It Is, Cynthia Matossian, MD, FACS, shared pearls for ophthalmologists ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Finding a clinical trial that is a good fit can be challenging. Here's how to get the most out of your clinical trial search.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...